Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effectiveness and Safety of Cofrogliptin and Linagliptin as add-on Therapy to Insulin in Chinese Adults With Type 2 Diabetes Mellitus: a Multicenter, Prospective Real-world Study (COLOR-REAL)

NCT07198932 is registered in ClinicalTrials.gov with Yanbing Li as lead sponsor.

NCT NCT07198932
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07198932 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effectiveness and Safety of Cofrogliptin and Linagliptin as add-on Therapy to Insulin in Chinese Adults With Type 2 Diabetes Mellitus: a Multicenter, Prospective Real-world Study (COLOR-REAL)
Lead sponsor
Yanbing Li
Phase
Observational
Overall status
Not yet recruiting
Start date
October 1, 2025
Completion date
December 31, 2027
Enrollment
594 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes